Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors

NCT01678690 is registered in ClinicalTrials.gov with InnoPharmax Inc. as lead sponsor.

NCT NCT01678690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01678690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
Lead sponsor
InnoPharmax Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2012
Completion date
April 30, 2014
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumors